MOTS-c for Menopause: What the Evidence Shows
What human and animal studies show about MOTS-c for menopause, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Animal
- Human studies
- 1
- PubMed records, our ledger
- Animal studies
- 0
- PubMed records, our ledger
- Studies we summarised
- 2
- with an outcome for menopause
Evidence for menopause
Each row is an outcome related to menopause from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Ovariectomy-induced obesity | MOTS-c prevented ovariectomy-induced obesity and insulin resistance in mice. | Animal · mouse (not a human result) | Journal of molecular medicine 2019, PMID 30725119 |
| Bone loss | MOTS-c treatment significantly alleviated bone loss on micro-CT in ovariectomized mice. | Animal · mouse (not a human result) | Biochemical and biophysical research communications 2016, PMID 27237975 |
PubMed records for MOTS-c and menopause: 1 human, 0 animal (search counts, not studies we reviewed). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Menopause in plain terms
MedlinePlus describes menopause as the time when a person stops having periods and can no longer get pregnant.[3]
What MOTS-c studies measured closest to menopause
The nearest model is ovariectomy in mice: MOTS-c treatment prevented ovariectomy-induced obesity and insulin resistance, an animal result.[1]
In those ovariectomised mice MOTS-c increased brown fat activation and reduced fat accumulation and inflammatory invasion in white adipose tissue.[1]
Separate work in ovariectomised mice found MOTS-c at 5 mg/kg once a day for 12 weeks alleviated bone loss.[2]
The goal ledger's dated PubMed count for MOTS-c with menopause terms was 2 records tagged human and 0 tagged animal-only.
Calculated from source our PubMed count ledger; goal menopause; peptide MOTS-c; date 2026-10-02; query ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (menopaus*[tiab] OR postmenopaus*[tiab] OR perimenopaus*[tiab] OR climacteric[tiab] OR "hot flashes"[tiab] OR "hot flushes"[tiab] OR "vasomotor symptoms"[tiab]); human filter AND humans[mh]; animal filter AND (animals[mh] NOT humans[mh]); human count 2; animal count 0. Formula: counts as recorded in the goals.json ledger; tagged records are not necessarily treatment studies
Other peptides people research for menopause
All peptides for menopause, comparedCommon questions
Does MOTS-c help with menopause?
The strongest study we summarise for menopause is animal evidence, across 2 studies with an outcome for menopause. That is not proof it works in people.
Is MOTS-c approved for menopause?
No. MOTS-c is not FDA approved for any use, including menopause.
What is the best peptide for menopause?
There is no single answer. Our menopause overview compares each candidate by evidence grade and legal status rather than by popularity.
Does MOTS-c help menopause symptoms?
No study measured hot flushes or other menopause symptoms; the cited work is in ovariectomised mice and looked at fat, insulin and bone.[1]
More on MOTS-c
Sources
- 1MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction.Journal of molecular medicine (Berlin, Germany) · 2019PMID 30725119Accessed 2 Oct 2026
- 2Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation.Biochemical and biophysical research communications · 2016PMID 27237975Accessed 2 Oct 2026
- 3Official web pageOfficial web page · web page
Found an error? Report a correction.